Literature DB >> 6669039

Continuous perifusion of dispersed anterior pituitary cells: technical aspects.

W S Evans, M J Cronin, M O Thorner.   

Abstract

Continuous perifusion of dispersed anterior pituitary cells is a powerful dynamic in vitro technique that complements the static incubation technique of primary culture. The major advantages of perifusion include the ability to challenge cells with test substance in a pulsatile manner and to monitor the immediate response. Furthermore, the accumulation of hormonal product and proteolytic enzymes, with their potential effects on cell function, is essentially eliminated as a concern. Finally, although methods using static techniques are available, experiments using continuously perifused dispersed cells can be initiated soon after removal of the gland from the donor animal. We and others have found this system to be useful in the study of hormone secretion by the anterior pituitary. We expect that the system will lend itself equally well to investigations of other cellular processes involving the export of organic and inorganic substances.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6669039     DOI: 10.1016/s0076-6879(83)03019-0

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  3 in total

1.  Cholecystokinin cells purified by fluorescence-activated cell sorting respond to monitor peptide with an increase in intracellular calcium.

Authors:  R A Liddle; M A Misukonis; L Pacy; A E Balber
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

2.  Medium flow rate modulates autocrine-paracrine feedback of GH and PRL release by perifused GH3 cells.

Authors:  M E Stachura; C A Lapp; J M Tyler; Y S Lee
Journal:  In Vitro Cell Dev Biol       Date:  1990-05

3.  Effect of pulse frequency and amplitude of D-Trp6-luteinizing hormone-releasing hormone on the pulsatile secretion of prolactin and LH.

Authors:  T Rodriguez; E Bordiu; J A Rubio; A Duran; A L Charro
Journal:  J Endocrinol Invest       Date:  1993-09       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.